Study of CM512 Injection in Subjects With Moderate-to-severe Asthma

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Asthma

In brief

This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in subjects with moderate-to-severe asthma.

Key facts

Study ID

NCT07011524

Run by

Keymed Biosciences Co.Ltd

People needed

200

Starts

2025-08-19

Expected to finish

2027-07-21

Last updated by the study team

2025-08-28

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able to understand and comply with procedures of the protocol, and voluntarily sign the Informed Consent Form.
• Age ≥ 18 years old and ≤ 75 years old.
• Body mass index (BMI) ≥ 18.0 kg/(m*m).
• Documented treatment with medium to high dose Inhaled Corticosteroids (ICS) in combination with asthma controller medication for at least 3 months with a stable dose ≥1 month prior to Visit 1.
• Documented history of at least 1 severe asthma exacerbation events within 12 months, and at least one of the exacerbations should occur during the treatment of medium-to-high dose ICS.
• Asthma Control Questionnaire-6 (ACQ-6) score ≥1.5

You may not qualify if…

• Women of childbearing potential have a positive pregnancy test result during the screening period; women who are pregnant or lactating.
• With a history of drug abuse within the past 5 years before screening visit.
• Allergic or intolerant to CM512 injection or placebo components, or with a history of severe drug allergies or anaphylactic shock.
• With any medical or non-medical conditions that are not suitable for participation in this study by investigators.

Where it is running

• The First Clinical Hospital of Guangzhou Medical University — Guangzhou, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.